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icrovolt T-Wave Alternans for
rrhythmia Risk Stratification
n Left Ventricular Dysfunction
hich Patients Benefit?*
homas Klingenheben, MD
onn and Frankfurt, Germany
atients with left ventricular (LV) dysfunction are at high
isk of malignant ventricular tachyarrhythmias and may thus
enefit from prophylactic placement of an implantable
ardioverter-defibrillator (ICD). Several randomized trials
ave shown that in patients with severely depressed LV
unction and heart failure, primary preventive ICD therapy is
ffective in the setting of both ischemic (1,2) and nonischemic
eart disease (2,3). However, the number of patients to be
reated with an ICD to save 1 life is relatively high, indicating
low therapeutic efficacy if patient selection is based solely on
V function, which calls for further refinement of arrhythmia
isk stratification in these patient populations.
See page 166
Microvolt-level T-wave alternans (MTWA) has recently
ndergone extensive study in patients with congestive heart
ailure or LV dysfunction (4–10) and has been shown to be
redictive of ventricular arrhythmic events in various patient
opulations (11). In particular, many studies have focused on
atients without a prior history of ventricular tachyarrhythmic
vents, such as patients fulfilling clinical criteria of the popu-
ation included in the MADIT (Multicenter Automatic
efibrillator Implantation Trial)-II trial (7–10). In such
MADIT-II–type” patients, a non-negative (i.e., positive or
indeterminate”) test is associated with a high risk of arrhyth-
ic mortality (9). For example, one recent study demonstrated
hat ICD therapy was associated with a mortality benefit only
n MTWA–non-negative, but not in MTWA-negative, pa-
ients (10). Accordingly, a negative MTWA test can identify
atients who may not benefit from prophylactic ICD insertion
7,8). Similar findings were reported for patients with left
entricular dysfunction from any cause who had no history of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From the Cardiology Practice Bonn, Bonn, Germany; and the J. W. Goethe
niversity, Frankfurt, Germany.entricular tachyarrhythmias. In a study by Bloomfield et al.
6), 549 patients with LV dysfunction underwent MTWA
ssessment with total mortality and nonfatal sustained ventric-
lar arrhythmias being the primary end point. Left ventricular
jection fraction (LVEF) averaged 25  6%, and one-half of
he patients had ischemic cardiomyopathy. Over a follow-up
eriod of 20  6 months, a primary end point event occurred
n 15% of patients with an abnormal (i.e., positive or “indeter-
inate”) MTWA test. The negative predictive value of
TWA at 2 years was 97.5%. The authors concluded that, in
his population, MTWA can identify a low-risk group unlikely
o benefit from prophylactic ICD therapy (6).
The study by Cantillon et al. (12) in this issue of the Journal
dds to the understanding of arrhythmia risk assessment in
atients with LV dysfunction. From a population of patients
eferred for evaluation of syncope, nonsustained ventricular
achycardia (NSVT), or both, the authors identified patients
ith LV dysfunction (defined as LVEF35%), of whom 76%
ad ischemic heart disease. Mean LVEF averaged 26  7%,
nd 84% of patients had New York Heart Association func-
ional class II or III heart failure. Patients underwent electro-
hysiologic testing (EPS), and MTWA assessment was per-
ormed during the same procedure, i.e., with the use of atrial
acing in order to increase heart rate. Patients were followed
or 38  11 months. Sixty-nine percent of patients tested
TWA–non-negative. On multivariate analysis, MTWA
as a significant predictor of the primary end point, with a
azard ratio of 2.37, whereas EPS was a less effective predictor
f arrhythmia-free survival and all-cause mortality. The
TWA-negative patients had improved 2-year arrhythmia-
ree survival compared with MTWA–non-negative patients
81% vs. 66%; p  0.0001) (12). In patients with ischemic
eart disease, the arrhythmia-free survival in MTWA neg-
tive patients was 79% and thus much lower than in
reviously published studies in patients with ischemic car-
iomyopathy (6–8). Because all patients underwent EPS,
he investigators also had the opportunity to elucidate its
ole in relation to MTWA testing. They did not find a
ignificant agreement between the 2 methods: The propor-
ion of patients with concordant and discordant results
etween EPS and MTWA was comparable. Also, if pa-
ients with ischemic and nonischemic LV dysfunction were
nalyzed separately, there was no strong agreement between
TWA and EPS in either group. However, combining the
tests added to the overall negative predictive value, which
as 85% over 2 years if patients tested negative during both
PS and MTWA assessment (12).
At first glance, the results of this study are in contrast to
arlier studies of MTWA in patients with congestive heart
ailure or LV dysfunction, particularly with respect to the
egative predictive value of MTWA (4–8). The present
tudy included patients referred for evaluation of syncope
nd/or NSVT, thus representing a higher-risk population in
hom a higher ventricular tachyarrhythmic event rate can
e assumed. In particular, 16% of the patients had suffered
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July 10, 2007:174–5 Editorial Commentyncope before inclusion (12), which in the setting of LV
ysfunction may be due to sustained ventricular tachyar-
hythmias. The present study population therefore differs
rom a “pure” primary prevention cohort.
The mode of MTWA testing represents a potential
imitation of the present study: MTWA was assessed
nvasively using atrial pacing, whereas in the earlier studies
TWA was assessed noninvasively using exercise-induced
eart rate increase. Results of a recent study suggested that
he predictive accuracy of invasive MTWA assessment may
e inferior to the noninvasive approach although their
egative predictive value seem to be similar (13).
Furthermore, the comparison of MTWA and EPS in the
resent study is hampered by the inhomogeneity of the
atient population. It is known that EPS yields different
redictive efficacy in ischemic and nonischemic heart dis-
ase. In the recently presented ABCD (Alternans Before
ardioverter-Defibrillator) trial (14), MTWA and EPS
ere studied in patients with ischemic cardiomyopathy,
VEF 40%, NSVT, and no prior ventricular tachy-
rrhythmic events. In that study, both tests were equivalent
n predicting appropriate ICD shocks or arrhythmic death,
nd their negative predictive values were 95%, rising to 98%
f both tests were combined (14).
hich patients may benefit from MTWA-guided anti-
rrhythmic therapy? In summary, the study of Cantillon et
l. (12) extends our knowledge about the use of MTWA in
atients with LV dysfunction and additional risk profiles
NSVT or syncope). In that population, MTWA alone may
ot be sufficiently effective to select patients to benefit (or
ot) from prophylactic ICD therapy. Putting the currently
vailable studies of MTWA in LV dysfunction in perspec-
ive, it can be concluded that the predictive efficacy of the test
s largely dependent on the patient population studied. Because
he pretest probability of a ventricular tachyarrhythmic event
iffers according to the underlying pathology of LV dysfunc-
ion and to the presence or absence of additional clinical risk
eatures, recommendations on the use of MTWA should be
ased on interventional trials in well defined patient popula-
ions. Such studies are currently underway (15–17) and may
elp to define the role of MTWA in a strategy of cost-effective
rimary preventive ICD therapy.
eprint requests and correspondence: Dr. Thomas Klingenhe-
en, Assistant Professor of Medicine, Praxis für Kardiologie, Im
ühlenbach 2 B, D-53127 Bonn, Germany. E-mail: klingenheben@
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